Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part ...

Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028DURHAM, N.C., Jan. 08, 2026 (GLOBE ...
Healio

Expert shares tips for safe subretinal delivery of gene therapy

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — Best practices for safe subretinal delivery of gene therapy were presented at the Retina ...
Healio

Robotics could optimize subretinal delivery of gene therapies

Please provide your email address to receive an email when new articles are posted on . Injection in the subretinal space, currently performed or investigated for several cell-based and gene therapy ...
GEN

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III

When the FDA approved Spark Therapeutics’ Luxturna in December 2017, gene therapy became a household concept. Chatter about gene therapy curing blindness became hot fodder at dinner tables and ...
Business Wire

Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial

LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the first surgery using its proprietary Orbit™ Subretinal Delivery System ...